PAK4 and Patent ductus arteriosus: More importantly, our findings lay down a solid base for further testing the combined effects of PAK1 and PAK4 on the tumour immune response of PDA using selective PAK inhibitors, which will provide a clear guide for the clinical translation of this basic research work.